The tumor progression‐associated human melanoma antigen P3.58 mediates monocyte‐lymphocyte interactions in vitro
- 1 December 1988
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 18 (12) , 2097-2100
- https://doi.org/10.1002/eji.1830181236
Abstract
The melanoma‐associated antigen P3.58 is rarely found on benign proliferating melanocytes but is consistently expressed on advanced malignant melanomas which have a high probability of metastasis. Previous studies have shown that its expression on normal tissues is limited to vascular endothelia and lymphoid follicle germinal centers and that it is also expressed by activated monocytes in vitro. In the studies reported here, anti‐P3.58 monoclonal antibodies (mAb) were shown to partially inhibit antigen‐specific and anti‐CD3‐induced T cell proliferation and to completely block a lymphocytelmonocyte clustering which occurs in the absence of added antigen. This inhibition is highly specific for P3.58 mAb and was not affected by mAb directed to major histocompatibility complex or T cell antigens. P3.58 therefore seems to be involved in an antigen‐independent attraction or adhesion of lymphocytes. P3.58 is the second example (HLA‐DR being the first) of an association between the expression of an immune function‐associated molecule and the development of metastatic disease in melanoma.This publication has 16 references indexed in Scilit:
- Glycoprotein P3.58, associated with tumor progression in malignant melanoma, is a novel leukocyte activation antigenInternational Journal of Cancer, 1988
- Interferon‐induced alterations in metastatic capacity, class‐1 antigen expression and natural killer cell sensitivity of melanoma cellsInternational Journal of Cancer, 1987
- Monoclonal antibodies to LFA-1 and to CD4 inhibit the mixed leukocyte reaction after the antigen-dependent clustering of dendritic cells and T lymphocytes.The Journal of Experimental Medicine, 1987
- The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodiesInternational Journal of Cancer, 1986
- A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in manEuropean Journal of Immunology, 1986
- Phenotypic dynamics of tumor progression in human malignant melanomaInternational Journal of Cancer, 1985
- In situ analysis of antigens on malignant and benign cells of the melanocyte lineage. Differential expression of two surface molecules, gp75 and p89.The Journal of Experimental Medicine, 1985
- The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA‐DR antigens on the tumor cellsInternational Journal of Cancer, 1984
- Biological Diversity in Metastatic Neoplasms: Origins and ImplicationsScience, 1982
- Thickness, Cross-Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous MelanomaAnnals of Surgery, 1970